Nassim Usman - 28 Jun 2024 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role
Director
Signature
/s/ Ruoyu Chen, as attorney-in-fact for Nassim Usman
Issuer symbol
GYRE
Transactions as of
28 Jun 2024
Net transactions value
-$17,515
Form type
4
Filing time
01 Jul 2024, 18:00:33 UTC
Previous filing
02 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GYRE Common Stock Options Exercise $23,922 +3,452 +211% $6.93 5,088 28 Jun 2024 Direct
transaction GYRE Common Stock Sale $41,438 -3,452 -68% $12.00 1,636 28 Jun 2024 Direct F1, F2
holding GYRE Common Stock 563 28 Jun 2024 By The Usman Family Trust
holding GYRE Common Stock 77 28 Jun 2024 By Nassim Usman IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GYRE Stock Option (Right to Buy) Options Exercise $0 -3,452 -1.2% $0.000000 278,200 28 Jun 2024 Common Stock 3,452 $6.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Nassim Usman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.025. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 This option is vested in full.